Merit Medical Systems: Sustained Operating Momentum and Governance Clarity Support Continued Buy Rating

Canaccord Genuity analyst John Young CFA has maintained their bullish stance on MMSI stock, giving a Buy rating today.

John Young CFA has given his Buy rating due to a combination of factors that underscore Merit Medical Systems’ solid operating momentum and resilient growth profile. The company’s preliminary fourth-quarter revenue range modestly surpasses both Street expectations and prior guidance, indicating healthy underlying demand and effective execution despite a dynamic operating environment. Management’s decision to preannounce results appears intended to provide transparency to investors following the unexpected board resignation of founder Fred Lampropoulos, which helps mitigate governance-related uncertainty.

John also interprets the leadership transition as a sign of confidence that the current executive team is fully capable of driving the next phase of growth, supported by the appointment of an experienced lead independent director to fill the board vacancy. Looking into 2026, he expects investor attention to center on the commercialization path for Wrapsody without temporary add-on reimbursement, the company’s ability to sustain organic revenue expansion, its discipline and opportunity set in tuck-in acquisitions, and further margin enhancement. Collectively, these elements support a favorable risk/reward profile in his view, justifying a continued Buy recommendation on MMSI shares.

In another report released today, TipRanks – OpenAI also upgraded the stock to a Buy with a $104.00 price target.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year.